Literature DB >> 26149988

Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate.

Joseph M Sturino1, Karina Pokusaeva2, Robert Carpenter3.   

Abstract

Clostridium difficile is a leading cause of antibiotic-associated diarrhea and the etiologic agent responsible for C. difficile infection. Toxin A (TcdA) and toxin B (TcdB) are nearly indispensable virulence factors for Clostridium difficile pathogenesis. Given the toxin-centric mechanism by which C. difficile pathogenesis occurs, the selective sequestration with neutralization of TcdA and TcdB by nonantibiotic agents represents a novel mode of action to prevent or treat C. difficile-associated disease. In this preclinical study, we used quantitative enzyme immunoassays to determine the extent by which a novel drug, calcium aluminosilicate uniform particle size nonswelling M-1 (CAS UPSN M-1), is capable of sequestering TcdA and TcdB in vitro. The following major findings were derived from the present study. First, we show that CAS UPSN M-1 efficiently sequestered both TcdA and TcdB to undetectable levels. Second, we show that CAS UPSN M-1's affinity for TcdA is greater than its affinity for TcdB. Last, we show that CAS UPSN M-1 exhibited limited binding affinity for nontarget proteins. Taken together, these results suggest that ingestion of calcium aluminosilicate might protect gastrointestinal tissues from antibiotic- or chemotherapy-induced C. difficile infection by neutralizing the cytotoxic and proinflammatory effects of luminal TcdA and TcdB.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26149988      PMCID: PMC4649210          DOI: 10.1128/AAC.05050-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

2.  Induction of cytokines in a macrophage cell line by proteins of Clostridium difficile.

Authors:  Prerna Vohra; Ian R Poxton
Journal:  FEMS Immunol Med Microbiol       Date:  2012-04-04

Review 3.  Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties.

Authors:  R H Barker; R Dagher; D M Davidson; J K Marquis
Journal:  Aliment Pharmacol Ther       Date:  2006-12       Impact factor: 8.171

4.  Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association.

Authors:  Stephen J Demarest; Jared Salbato; Marikka Elia; Jingping Zhong; Theresa Morrow; Trevin Holland; Katie Kline; Gary Woodnutt; Bruce E Kimmel; Geneviève Hansen
Journal:  J Mol Biol       Date:  2005-03-11       Impact factor: 5.469

5.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

6.  Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes.

Authors:  B A Feltis; S M Wiesner; A S Kim; S L Erlandsen; D L Lyerly; T D Wilkins; C L Wells
Journal:  Shock       Date:  2000-12       Impact factor: 3.454

7.  Monocytes are highly sensitive to clostridium difficile toxin A-induced apoptotic and nonapoptotic cell death.

Authors:  K Solomon; J Webb; N Ali; R A Robins; Y R Mahida
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

8.  Short-term safety and efficacy of calcium montmorillonite clay (UPSN) in children.

Authors:  Nicole J Mitchell; Justice Kumi; Mildred Aleser; Sarah E Elmore; Kristal A Rychlik; Katherine E Zychowski; Amelia A Romoser; Timothy D Phillips; Nii-Ayi Ankrah
Journal:  Am J Trop Med Hyg       Date:  2014-08-18       Impact factor: 2.345

9.  Sequencing and analysis of the gene encoding the alpha-toxin of Clostridium novyi proves its homology to toxins A and B of Clostridium difficile.

Authors:  F Hofmann; A Herrmann; E Habermann; C von Eichel-Streiber
Journal:  Mol Gen Genet       Date:  1995-06-25

Review 10.  Clostridium difficile-associated disease: new challenges from an established pathogen.

Authors:  Rebecca H Sunenshine; L Clifford McDonald
Journal:  Cleve Clin J Med       Date:  2006-02       Impact factor: 2.321

View more
  5 in total

Review 1.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

2.  Black Seed Oil, Bentonite Clay, and Probiotics: A Comprehensive Holistic Cure for Clostridium difficile Infection in a 2-Year-Old Female Child.

Authors:  Emily Littman; Nicole Winningham; Tana B Carson; Ivette M Hidalgo
Journal:  Case Rep Infect Dis       Date:  2022-05-29

Review 3.  Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.

Authors:  Stefano Di Bella; Paolo Ascenzi; Steven Siarakas; Nicola Petrosillo; Alessandra di Masi
Journal:  Toxins (Basel)       Date:  2016-05-03       Impact factor: 4.546

Review 4.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

Review 5.  The Importance of Therapeutically Targeting the Binary Toxin from Clostridioides difficile.

Authors:  Dinendra L Abeyawardhane; Raquel Godoy-Ruiz; Kaylin A Adipietro; Kristen M Varney; Richard R Rustandi; Edwin Pozharski; David J Weber
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.